Validation of a Genetic Signature For Women With Node-Negative Breast Cancer
A 70-genetic signature was shown in a single institution to have prognostic value in patients with node-negative breast cancer. The purpose of this study was to validate this signature in independent patient samples. Hazard ratios were estimated by IDDI’s methodology group of experts, to compare rates in high versus low risk groups for the time related endpoints. The models were or not stratified by a clinicpathological risk group to verify if the gene signature adds independent prognostic information to clinic-pathological risk factor.